NSE - Delayed Quote INR

EMCURE PHARMACEUTICALS L (EMCURE.NS)

1,361.40
-14.50
(-1.05%)
At close: June 13 at 3:30:03 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
78,959,970
78,959,970
66,582,510
59,310,760
57,662,040
Cost of Revenue
31,466,030
31,466,030
24,754,170
22,605,270
22,331,560
Gross Profit
47,493,940
47,493,940
41,828,340
36,705,490
35,330,480
Operating Expense
36,646,680
36,646,680
32,655,180
27,299,230
24,456,300
Operating Income
10,847,260
10,847,260
9,173,160
9,406,260
10,874,180
Net Non Operating Interest Income Expense
-1,757,840
-1,757,840
-2,371,470
-1,797,710
-1,512,570
Pretax Income
9,713,490
9,713,490
7,272,280
7,472,150
9,725,480
Tax Provision
2,638,820
2,638,820
1,996,530
1,853,700
2,699,920
Net Income Common Stockholders
6,813,320
6,813,320
4,981,830
5,320,190
6,622,000
Diluted NI Available to Com Stockholders
6,813,320
6,813,320
4,981,830
5,320,190
6,622,000
Basic EPS
36.43
--
27.57
29.43
36.63
Diluted EPS
36.43
--
27.57
29.43
36.63
Basic Average Shares
187,024.98
--
180,719.48
180,792.76
180,792.76
Diluted Average Shares
187,024.98
--
180,719.48
180,792.76
180,792.76
Rent Expense Supplemental
--
--
71,400
67,060
53,530
Total Expenses
68,112,710
68,112,710
57,409,350
49,904,500
46,787,860
Net Income from Continuing & Discontinued Operation
6,813,320
6,813,320
4,981,830
5,320,190
6,622,000
Normalized Income
6,888,906.56
6,888,906.56
5,053,875.46
5,512,583.46
6,639,084.45
Interest Income
--
--
207,590
118,340
101,970
Interest Expense
1,757,840
1,757,840
2,371,470
1,916,050
1,614,540
Net Interest Income
-1,757,840
-1,757,840
-2,371,470
-1,797,710
-1,512,570
EBIT
11,471,330
11,471,330
9,643,750
9,388,200
11,340,020
EBITDA
15,313,110
15,313,110
12,767,820
11,989,380
13,788,570
Reconciled Cost of Revenue
31,466,030
31,466,030
24,754,170
22,605,270
22,331,560
Reconciled Depreciation
3,841,780
3,841,780
3,124,070
2,601,180
2,448,550
Net Income from Continuing Operation Net Minority Interest
6,813,320
6,813,320
4,981,830
5,320,190
6,622,000
Total Unusual Items Excluding Goodwill
-103,780
-103,780
-99,310
-255,870
-23,650
Total Unusual Items
-103,780
-103,780
-99,310
-255,870
-23,650
Normalized EBITDA
15,416,890
15,416,890
12,867,130
12,245,250
13,812,220
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-28,193.44
-28,193.44
-27,264.54
-63,476.54
-6,565.55
3/31/2022 - 7/10/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VENUSREM.NS Venus Remedies Limited
457.30
+2.60%
 
HIKAL.NS Hikal Limited
375.80
-0.88%
 
INNOVACAP.NS Innova Captab Limited
907.30
-4.04%
 
KILITCH.NS Kilitch Drugs (India) Limited
454.50
-0.01%
 
WANBURY.NS Wanbury Limited
312.20
+3.86%
 
MEDICAMEQ.NS Medicamen Biotech Limited
412.75
-1.40%
 
VIKRAMTH.BO Vikram Thermo (India) Limited
167.35
-0.12%
 
SOLARA.NS Solara Active Pharma Sciences Limited
505.15
-0.75%
 
WINDLAS.NS Windlas Biotech Limited
932.55
+0.20%
 
GUJTHEM.BO Gujarat Themis Biosyn Limited
333.75
-3.69%